Changes in Asthma Maintenance Therapy Prescribing Patterns Following the 2006 Long-acting β-Agonist FDA Drug Warning-Reference-Cited by-同舟云学术

Changes in Asthma Maintenance Therapy Prescribing Patterns Following the 2006 Long-acting β-Agonist FDA Drug Warning

Published:2017-04 Issue:4 Volume:39 Page:697-701
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Winter Jonathan D.,Reetz Matthew R.,Kerns J. William,Winter Katherine M.,Sabo Roy T.,Krugman Scott D.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference12 articles.

1. Post Market Drug Safety Information for Patients and Providers: Advair Diskus, Advair HFA, Brovana, Foradil, Perforomist, Serevent Diskus, and Symbicort Information (Long Acting Beta Agonists). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm. Accessed August 26, 2016.

2. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol;Nelson;Chest,2006

3. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment;Castle;BMJ,1993

4. Misleading data analyses in salmeterol (SMART) study;Lurie;Lancet,2005

5. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid;Greening;Lancet,1994

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes;Pharmacoepidemiology and Drug Safety;2020-08-12

2. Do drug‐related safety warnings have the expected impact on drug therapy? A systematic review;Pharmacoepidemiology and Drug Safety;2020-02-11

3. Risk Communication in a Pharmacovigilance Environment;Clinical Therapeutics;2017-04

4. Risk Evaluation and Mitigation Strategies (REMS), Pemoline, and What Is a Signal?;Clinical Therapeutics;2017-04